Acute Exacerbations in Idiopathic Pulmonary Fibrosis

  1. Fernando J. Martinez, MD, MS
  1. From the University of Michigan, Ann Arbor, MI 48109.

    IN RESPONSE:

    Drs. Crowley, Kelly, and Egan raise several important points regarding our recent report that identified a high incidence of rapidly progressive pulmonary disease in the placebo group of a multicenter trial of interferon-γ1b in patients with IPF. The identification of patients who succumbed to a rapid, fatal deterioration versus those who did not provides important, clinically relevant information.

    Examination of baseline characteristics of patients who died abruptly of IPF-related causes and those of patients who died following an IPF-related subacute deterioration revealed a similar baseline mean predicted FVC (64% [SD, 12%] vs. 60% [SD, 12%]; P = 0.29) and mean DLco (33% [SD, 6%] vs. 31% [SD, 7%]; P = …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med February 7, 2006 vol. 144 no. 3 218-219
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues